**Table B9. Lipid Modifying Agents: Data Abstraction: Study Funder and Conflicts of Interest**

|   |   | **Study characteristics, from the publication** |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Journal** | **Study funder** | **Percentage of authors employed by pharmaceutical industry** | **Percentage of authors with COI from industry** | **What company makes intervention drug?** | **What company makes comparator drug?** | **Was there any assistance authoring the publication?** | **Did the publication indicate that the trial was registered?** |
| Ballantyne, 2005 | American Heart Journal | Merck & Co./Schering Plough Pharmaceuticals | 3/5 (60%) | 2/2 (0%) | Ezetimibe/ simvastatin: Merck (Vytorin) | Atorvastatin: Pfizer (Lipitor) | NR | No |
| Ballantyne, 2007 | The American Journal of Cardiology | NR; (clearly AstraZeneca) | 2/7 (29%) | 1/5 (20%) | Rosuvastatin: AstraZeneca (Crestor) | Combination Rosuvastatin/ Ezetimibe. Ezetimibe: Merck | Yes | No |
| Blagden, 2007 | Current Medical Research and Opinion | Schering-Plough UK Limited | 1/2 (50%) | 0/1 (0%) | Ezetimibe: Merck atorvastatin: Pfizer (Lipitor) and generic | Placebo/ atorvastatin: generic | Yes | No |
| Catapano, 2006 | Current Medical Research and Opinion | Merck & Co./Schering-Plough Pharmaceuticals | 4/7 (57%) | 0/3 (0%) | Ezetimibe/ simvastatin: Merck | Rosuvastatin: AstraZeneca (Crestor) | Yes  | Yes |
| Conard, 2008 | The American Journal of Cardiology | Merck & Co./Schering-Plough Pharmaceuticals | 5/8 (63%) | 3/3 (100%) | Ezetimibe: Merck plus Atorvastatin: Pfizer and generic | Atorvastatin: Pfizer and generic | Yes | No |
| Constance, 2007 | Diabetes, Obesity and Metabolism | Merck & Co./Schering Plough Pharmaceuticals | 5/8 (63%) | 0/3 (0%) | Ezetimibe/ simvastatin: Merck (Vytorin) | Atorvastatin: Pfizer (Lipitor) | NR | No |
| Goldberg, 2006 | Mayo Clinic Proceedings | Merck & Co./Schering Plough Pharmaceuticals | 4/8 (50%) | 4/4 (100%)  | Ezetimibe/ simvastatin: Merck (Vytorin) | Atorvastatin: Pfizer (Lipitor) | Yes | No |
| Gouni-Berthold, 2008 | Atherosclerosis | MSD Sharp & Dohme, Germany, and the Wilhelm-Doerenkamp Foundation, Cologne | 0/13 (0%) | 0/13 (0%) | Ezetimibe: Merck Simvastatin: Merck and generic | Combination ezetimibe/ simvastatin: Merck | NR | No |
| Landray, 2006 | American Journal of Kidney Diseases | Merck & Co. | 0 | 0 | Ezetimibe: Merck | Simvastatin: Merck | NR | Yes |
| Leiter, 2008 | The American Journal of Cardiology | Merck & Co./Schering-Plough Pharmaceuticals | 5/8 (63%) | 3/3 (100%) | Ezetimibe: Merck plus Atorvastatin: Pfizer and generic | Atorvastatin: Pfizer and generic | Yes | Yes |
| Patel, 2006 | International Journal of Clinical Practice | Schering- Plough Pharmaceuticals | 0/2 (0%) | 1/2 (50%)  | Ezetimibe/ simvastatin: Merck | Placebo/ simvastatin: generic  | NR | No |
| Pearson, 2005 | Mayo Clinic Proceedings | Merck & Co./Schering Plough Pharmaceuticals | 3/6 (50%) | 2/3 (66%)  | Ezetimibe plus statin therapy: Merck (ezetimibe) | Placebo plus statin therapy: NA | No | No |
| Reckless, 2008 | International Journal of Clinical Practice | Merck & Co./Schering Plough Pharmaceuticals | 6/10 (60%) | Can't be determined | Ezetimibe/ simvastatin: Merck (Vytorin) | Statin drug: not specified | Yes | No |
| Roeters van Lennep, 2008 | Current Medical Research and Opinion | Merck & Co.; Sharp and Dohme and Schering Plough Pharmaceuticals | 0/6 (0%) | 3/6 (50%) | Atorvastatin: Pfizer and genericSimvastatin: Merck | Ezetimibe/ simvastatin: MerckEzetimibe monotherapy: Merck  | NR | Yes |